ECRIN Meeting will address the challenges for clinical trial research in Europe in Lyon - France
28 March 2011 - 8 March 2011
Austria
The meeting will address health and research challenges in Europe and the responses that clinical trials can bring in areas such as ageing, chronic diseases and personalised medicines, rare diseases, need for evidence-based practice, impact on health and costs, scientific competitiveness, and new models for health innovation.
“Critical mass in terms of population size, healthcare and levels of expertise should make Europe the first place to go for clinical trials”, says Jacques Demotes-Mainard, ECRIN Coordinator.
ECRIN was developed to support multinational clinical research, thus improving the competitiveness and attractiveness of Europe. It is a pan-European infrastructure based on the connection of national networks and hubs of clinical research infrastructures. Its coordination is hosted by INSERM, the French National Institute of Health and Medical Research. It currently covers 14 EU countries.
The ECRIN consortium is designed to provide a European not-for-profit platform for the support to trans-European clinical research projects. It aims to maintain Europe’s leadership on clinical trials by providing an EU-wide services platform. The network aims to help academics and small or medium-sized companies to do the sort of cross-border research that pharmaceutical companies, with their many subsidiaries, have been doing for years.
ECRIN has been developed since 2004 through the European Commission’s multiannual Framework Programmes for Research and Technological Development (FP). From 2011 it becomes a member-state-funded international organisation under the ERIC (European Research Infrastructure Consortium) status, with operation costs around 3.5 million Euros a year.
ECRIN provides the key technical capacity to address several of the upcoming grand challenges for Europe. By improving multinational clinical trials ECRIN speeds up the development of medicines and disease prevention and will embrace some of the needs of basic research as well as of the biotech and pharmaceutical industries. In addition, ECRIN fosters comparative effectiveness research and treatment optimisation studies, thus resulting in improved and evidence-based healthcare strategies and in major cost containment for the public health systems. Finally, ECRIN also strongly boost political and scientific momentum to harmonise ethical, legal and quality standards across Europe.
2011 is an important milestone for clinical trials in Europe. For one thing, the FP7 is funding multinational clinical trials for the first time. Also, the European Clinical Trials Directive, which sets the legal framework for clinical trials in the EU, is due for a revision in 2012, and 2011 will be packed with consultations and debates between the European Commission and all relevant stakeholders prior to the publication of the Commission’s project.Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute which operates under the joint authority of the French Ministry of Health and French Ministry of Research.
As the only French public research institute to focus entirely on human health, in 2008 Inserm took on the responsibility for the strategic, scientific and operational coordination of biomedical research. Since the adoption of a decree in March 2009, scientific monitoring and expertise are also part of the Institute’s official missions.
To conduct its research policy as effectively as possible, Inserm has a wide range of facilities, either directly involved in fundamental research, or in close contact with patients, thanks to their cooperation with other training programs in major innovative projects. Large epidemiological surveys (registers and cohorts) are essential for implementing a high-quality public health policy.
From the outset, Inserm has forged close partnerships with the other public and private research establishments as well as hospitals to fulfil its missions. 80% of Inserm’s 318 research units are currently set up in university hospitals or cancer research centers. The research campuses of the French National Center for Scientific Research (CNRS), along with the Pasteur and Curie Institutes, also houses Inserm research divisions. With the law on the independence of universities placing them at the heart of the research policy, they will also be a key partner of Inserm.
Lastly, Inserm plays a leading role in creating the European Research Area and boosts its standing abroad through close partnerships with teams and partner laboratories abroad.
“Critical mass in terms of population size, healthcare and levels of expertise should make Europe the first place to go for clinical trials”, says Jacques Demotes-Mainard, ECRIN Coordinator.
ECRIN was developed to support multinational clinical research, thus improving the competitiveness and attractiveness of Europe. It is a pan-European infrastructure based on the connection of national networks and hubs of clinical research infrastructures. Its coordination is hosted by INSERM, the French National Institute of Health and Medical Research. It currently covers 14 EU countries.
The ECRIN consortium is designed to provide a European not-for-profit platform for the support to trans-European clinical research projects. It aims to maintain Europe’s leadership on clinical trials by providing an EU-wide services platform. The network aims to help academics and small or medium-sized companies to do the sort of cross-border research that pharmaceutical companies, with their many subsidiaries, have been doing for years.
ECRIN has been developed since 2004 through the European Commission’s multiannual Framework Programmes for Research and Technological Development (FP). From 2011 it becomes a member-state-funded international organisation under the ERIC (European Research Infrastructure Consortium) status, with operation costs around 3.5 million Euros a year.
ECRIN provides the key technical capacity to address several of the upcoming grand challenges for Europe. By improving multinational clinical trials ECRIN speeds up the development of medicines and disease prevention and will embrace some of the needs of basic research as well as of the biotech and pharmaceutical industries. In addition, ECRIN fosters comparative effectiveness research and treatment optimisation studies, thus resulting in improved and evidence-based healthcare strategies and in major cost containment for the public health systems. Finally, ECRIN also strongly boost political and scientific momentum to harmonise ethical, legal and quality standards across Europe.
2011 is an important milestone for clinical trials in Europe. For one thing, the FP7 is funding multinational clinical trials for the first time. Also, the European Clinical Trials Directive, which sets the legal framework for clinical trials in the EU, is due for a revision in 2012, and 2011 will be packed with consultations and debates between the European Commission and all relevant stakeholders prior to the publication of the Commission’s project.Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute which operates under the joint authority of the French Ministry of Health and French Ministry of Research.
As the only French public research institute to focus entirely on human health, in 2008 Inserm took on the responsibility for the strategic, scientific and operational coordination of biomedical research. Since the adoption of a decree in March 2009, scientific monitoring and expertise are also part of the Institute’s official missions.
To conduct its research policy as effectively as possible, Inserm has a wide range of facilities, either directly involved in fundamental research, or in close contact with patients, thanks to their cooperation with other training programs in major innovative projects. Large epidemiological surveys (registers and cohorts) are essential for implementing a high-quality public health policy.
From the outset, Inserm has forged close partnerships with the other public and private research establishments as well as hospitals to fulfil its missions. 80% of Inserm’s 318 research units are currently set up in university hospitals or cancer research centers. The research campuses of the French National Center for Scientific Research (CNRS), along with the Pasteur and Curie Institutes, also houses Inserm research divisions. With the law on the independence of universities placing them at the heart of the research policy, they will also be a key partner of Inserm.
Lastly, Inserm plays a leading role in creating the European Research Area and boosts its standing abroad through close partnerships with teams and partner laboratories abroad.